Jefferies resumed coverage on Scholar Rock with a new price target
$SRRK
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Jefferies resumed coverage of Scholar Rock with a rating of Buy and set a new price target of $50.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/9/2025 | $53.00 | Buy | BofA Securities |
| 9/17/2025 | $45.00 | Overweight | Barclays |
| 9/15/2025 | $51.00 | Outperform | Leerink Partners |
| 8/21/2025 | $50.00 | Buy | Jefferies |
| 7/30/2025 | $53.00 | Strong Buy | Raymond James |
| 7/17/2025 | Overweight | Cantor Fitzgerald | |
| 11/26/2024 | $40.00 → $50.00 | Buy | H.C. Wainwright |
| 10/7/2024 | $30.00 → $35.00 | Buy | H.C. Wainwright |
4 - Scholar Rock Holding Corp (0001727196) (Issuer)
4 - Scholar Rock Holding Corp (0001727196) (Issuer)
4 - Scholar Rock Holding Corp (0001727196) (Issuer)
BofA Securities initiated coverage of Scholar Rock with a rating of Buy and set a new price target of $53.00
Barclays initiated coverage of Scholar Rock with a rating of Overweight and set a new price target of $45.00
Leerink Partners initiated coverage of Scholar Rock with a rating of Outperform and set a new price target of $51.00
SCHEDULE 13D/A - Scholar Rock Holding Corp (0001727196) (Subject)
8-K - Scholar Rock Holding Corp (0001727196) (Filer)
SCHEDULE 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)
No other approvability issues cited in CRL Scholar Rock intends to resubmit the apitegromab Biologics License Application (BLA) upon resolution of Catalent Indiana LLC-related observations Scholar Rock (NASDAQ:SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the apitegromab Biologics License Application (BLA) for the treat
Scholar Rock (NASDAQ:SRRK, the "Company")), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today announced that the company granted inducement equity awards covering an aggregate of 120,800 shares of its common stock to 9 newly hired employees, consisting of inducement stock options to purchase an aggregate of 69,029 shares of common stock and inducement restricted stock units, covering an aggregate of 51,771 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth in the Comp
Scholar Rock (NASDAQ:SRRK, the "Company")), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today announced that the company granted inducement equity awards covering an aggregate of 426,250 shares of its common stock to 64 newly hired employees, consisting of inducement stock options to purchase an aggregate of 243,577 shares of common stock and inducement restricted stock units, covering an aggregate of 182,673 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth in the C
4 - Scholar Rock Holding Corp (0001727196) (Issuer)
4 - Scholar Rock Holding Corp (0001727196) (Issuer)
4 - Scholar Rock Holding Corp (0001727196) (Issuer)
- Former Vice President and Global HR Head of Oncology and Pharma Development at Novartis brings extensive leadership experience focused on talent, culture, and diversity Scholar Rock (NASDAQ:SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the appointment of Caryn Parlavecchio as Chief Human Resources Officer. She will join the executive team, bringing more than 20 years of experience as a senior leader and strategic executive in the biotechnology and pharmaceutical industries. This press release features multimedia. View the full release here: https://www.businesswire.co
SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)
SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)
SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)
No other approvability issues cited in CRL Scholar Rock intends to resubmit the apitegromab Biologics License Application (BLA) upon resolution of Catalent Indiana LLC-related observations Scholar Rock (NASDAQ:SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the apitegromab Biologics License Application (BLA) for the treat
Scholar Rock (NASDAQ:SRRK, the "Company")), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today announced that the company granted inducement equity awards covering an aggregate of 120,800 shares of its common stock to 9 newly hired employees, consisting of inducement stock options to purchase an aggregate of 69,029 shares of common stock and inducement restricted stock units, covering an aggregate of 51,771 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth in the Comp
Scholar Rock (NASDAQ:SRRK, the "Company")), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today announced that the company granted inducement equity awards covering an aggregate of 426,250 shares of its common stock to 64 newly hired employees, consisting of inducement stock options to purchase an aggregate of 243,577 shares of common stock and inducement restricted stock units, covering an aggregate of 182,673 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth in the C